Top 4 Health Care Stocks That May Rocket Higher This Month
Top 4 Health Care Stocks That May Rocket Higher This Month
Read More: Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
醫療保健領域超賣次數最多的股票爲買入被低估的公司提供了機會。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.
RSI是一種動量指標，它比較了股票在價格上漲的日子裏的強度與價格下跌時的強度。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。當 RSI 低於 30 時，資產通常被視爲超賣。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是該行業主要超賣參與者的最新名單，RSI接近或低於30。
Spruce Biosciences, Inc. (NASDAQ:SPRB)
斯普魯斯生物科學公司 （納斯達克股票代碼：SPRB）
- Spruce Biosciences completed target enrollment of CAHmelia-203 study in adult classic congenital adrenal hyperplasia. The company's stock has a 52-week low of $0.9550 .
- RSI Value: 27.25
- SPRB Price Action: Shares of Spruce Biosciences fell 14.2% to close at $1.18 on Thursday.
- Spruce Biosciences完成了針對成人典型先天性腎上腺增生症的Cahmelia-203研究的目標入組。該公司的股票有 52 周低點 0.9550 美元 。
- RSI 值： 27.25
- SPRB 價格走勢： 週四，Spruce Biosciences股價下跌14.2％，收於1.18美元。
Generation Bio Co. (NASDAQ:GBIO)
Generation Bio （納斯達克股票代碼：GBIO）
- TD Cowen downgraded the stock from Outperform to Market Perform. It has a 52-week low of $1.17.
- RSI Value: 16.32
- GBIO Price Action: Shares of Generation Bio dipped 50.2% to close at $1.20 on Thursday.
- 道明考恩將該股的評級從跑贏大盤下調至市場表現。它 創下 52 周低點 1.17 美元的。
- RSI 值： 16.32
- GBIO 價格走勢： 週四，Generation Bio股價下跌50.2％，收於1.20美元。
LumiraDx Limited (NASDAQ:LMDX)
LumiRadX 有限公司 （納斯達克股票代碼：LMDX）
- LumiraDx posted downbeat results for the second quarter. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "The submission of our first 510(k) application to the FDA for our COVID Ultra test represents a significant milestone in our ability to deliver on product expansion into the U.S. and could pave the way for additional submissions of other high performing assays on our Platform, many of which are already available in Europe and elsewhere and others which are in late stages of development." The company's stock has a 52-week low of $0.0850.
- RSI Value: 19.64
- LMDX Price Action: Shares of LumiraDx fell 11.3% to close at $0.0930 on Thursday.
- LumiRadX公佈了第二季度的悲觀業績。LumiRadX董事長兼首席執行官羅恩·茲萬齊格表示：“我們向美國食品藥品管理局提交了第一份510（k）COVID Ultra測試申請，這是我們向美國擴展產品能力的一個重要里程碑，可能爲在我們平台上提交更多其他高性能檢測方法鋪平道路，其中許多已經在歐洲和其他地方上市，還有一些處於開發後期階段。”該公司的股票持倉時間爲52周 低點爲0.0850美元。
- RSI 值： 19.64
- LMDX 價格走勢： 週四，LumiRadX股價下跌11.3％，收於0.0930美元。
Evelo Biosciences, Inc. (NASDAQ:EVLO)
Evelo Biosciences, Inc （納斯達克股票代碼：EVLO）
- Evelo Biosciences reported the primary endpoint in its Phase 2 clinical study with EDP2939 in moderate psoriasis was not achieved. The company also initiated a process to explore strategic alternatives. The company's 52-week low is $0.48.
- RSI Value: 20.36
- EVLO Price Action: Shares of Evelo Biosciences fell 11.2% to close at $0.8883 on Thursday.
- Evelo Biosciences報告說，其在中度牛皮癬中使用 EDP2939 進行的 2 期臨床研究的主要終點尚未實現。該公司還啓動了探索戰略替代方案的進程。該公司的52周低點爲0.48美元。
- RSI 值： 20.36
- EVLO 價格走勢： 週四，Evelo Biosciences股價下跌11.2％，收於0.8883美元。
Read More: Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
閱讀更多： Vertex Pharmicals、Gilead Sciences 和其他兩隻股票內部人士正在
